EUR 53.27
(0.12%)
Year | Eps | Eps Growth |
---|---|---|
2024 | 1.74 EUR | 28.89% |
2023 | 1.35 EUR | -25.82% |
2022 | 1.82 EUR | 15.92% |
2021 | 1.57 EUR | 11.35% |
2020 | 1.41 EUR | -10.19% |
2019 | 1.57 EUR | 23.62% |
2018 | 1.27 EUR | -7.97% |
2017 | 1.38 EUR | 5.34% |
2016 | 1.31 EUR | 2.34% |
2015 | 1.28 EUR | 0.0% |
Year | Eps | Eps Growth |
---|---|---|
2024 Q2 | 0.38 EUR | -2.56% |
2024 Q1 | 0.39 EUR | -18.75% |
2024 Q3 | 0.42 EUR | 10.53% |
2023 FY | - EUR | -25.82% |
2023 Q3 | 0.40 EUR | 326.44% |
2023 Q4 | 0.48 EUR | 20.0% |
2023 Q1 | 0.38 EUR | -33.33% |
2023 Q2 | 0.09 EUR | -75.32% |
2022 Q1 | 0.41 EUR | 0.0% |
2022 Q4 | 0.57 EUR | 78.12% |
2022 Q3 | 0.32 EUR | -38.46% |
2022 Q2 | 0.52 EUR | 26.83% |
2022 FY | - EUR | 15.92% |
2021 Q1 | 0.40 EUR | -6.98% |
2021 FY | - EUR | 11.35% |
2021 Q4 | 0.41 EUR | 17.14% |
2021 Q3 | 0.35 EUR | -14.63% |
2021 Q2 | 0.41 EUR | 2.5% |
2020 Q1 | 0.30 EUR | -40.0% |
2020 FY | - EUR | -10.19% |
2020 Q2 | 0.41 EUR | 36.67% |
2020 Q4 | 0.43 EUR | 59.26% |
2020 Q3 | 0.27 EUR | -34.15% |
2019 Q4 | 0.50 EUR | 42.86% |
2019 Q3 | 0.35 EUR | -5.41% |
2019 Q2 | 0.37 EUR | 8.82% |
2019 Q1 | 0.34 EUR | -10.53% |
2019 FY | - EUR | 23.62% |
2018 Q4 | 0.38 EUR | 35.71% |
2018 FY | - EUR | -7.97% |
2018 Q3 | 0.28 EUR | -6.67% |
2018 Q2 | 0.30 EUR | -3.23% |
2018 Q1 | 0.31 EUR | -31.11% |
2017 Q1 | 0.36 EUR | 0.0% |
2017 FY | - EUR | 5.34% |
2017 Q3 | 0.32 EUR | 6.67% |
2017 Q2 | 0.30 EUR | -16.67% |
2017 Q4 | 0.45 EUR | 40.63% |
2016 FY | - EUR | 2.34% |
2015 FY | - EUR | 0.0% |
Name | Eps | Eps Difference |
---|---|---|
Cegedim SA | -0.54 EUR | 422.222% |
Guerbet SA | 1.90 EUR | 8.421% |
Nexus AG | 1.39 EUR | -25.18% |
Bastide Le Confort Médical SA | -0.12 EUR | 1550.0% |
Revenio Group Oyj | 0.72 EUR | -141.667% |
Drägerwerk AG & Co. KGaA | 5.89 EUR | 70.458% |
Sartorius Aktiengesellschaft | 3.00 EUR | 42.0% |
LNA Santé SA | 2.29 EUR | 24.017% |
Medios AG | 0.79 EUR | -120.253% |
Equasens Société anonyme | 3.13 EUR | 44.409% |
Stratec SE | 1.07 EUR | -62.617% |